{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:20:21Z","timestamp":1787026821525,"version":"build-2736575974"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Advanced Parkinson\u2019s disease (aPD) patients have a high risk on definite nursing home admission. We analyzed the effectiveness of an in-and outpatient multidisciplinary rehabilitation, focusing on activities of daily living (ADL) and delaying definite nursing home admission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study included 24 aPD patients, who received a 6-week inpatient multidisciplinary rehabilitation program, including optimization of pharmacotherapy, which was followed by an individualized outpatient support program during 2\u2009years (intervention group). A non-randomized matched control group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200919), received care as usual. Primary endpoints consisted of the Amsterdam Linear Disability Scale (ALDS) and percentage of patients being able to live independently at home after 2\u2009years. Secondary endpoints included changes in medication (LEDD), motor performance (SCOPA-SPES), cognition (SCOPA-COG), hallucinations (NPI) and depression (BDI).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 83% of patients were able to return home after the 6-week inpatient intervention, and 65% still lived at home at 2\u2009years follow-up. Median ALDS scores after 2\u2009years in the intervention group were significantly better, compared to the control group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). All secondary endpoints had improved significantly vs. baseline directly after the 6-week inpatient rehabilitation, which had disappeared at 2\u2009years follow-up, with the exception of the daily dose of medication, which was significantly higher in the intervention group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This 2-year follow-up study showed that a combined multidisciplinary in\/outpatient rehabilitation program for aPD patients, was able to stabilize ADL functions, and finally delayed definite nursing home admissions in 65% of treated patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>filenumber M10.091051; ABR code NL32699.042.10.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2023.1128891","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:56:52Z","timestamp":1681347412000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Combined multidisciplinary in\/outpatient rehabilitation delays definite nursing home admission in advanced Parkinson\u2019s disease patients"],"prefix":"10.3389","volume":"14","author":[{"given":"Elien","family":"Steendam-Oldekamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Weerkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith M.","family":"Vonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan R.","family":"Bloem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teus","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1002\/mds.23834","article-title":"Health-related quality-of-life scales in Parkinson\u2019s disease: critique and recommendations","volume":"26","author":"Martinez-Martin","year":"2011","journal-title":"Mov Disord"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/cns.13549","article-title":"Quality of life in Parkinson\u2019s disease: a systematic review and meta-analysis of comparative studies","volume":"27","author":"Zhao","year":"2021","journal-title":"CNS Neurosci Ther"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/mdc3.13186","article-title":"Factors associated with health-related quality of life in late-stage Parkinson\u2019s disease","volume":"8","author":"Rosqvist","year":"2021","journal-title":"Mov Disord Clin Pract"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/mds.20279","article-title":"Impact of the motor complications of Parkinson\u2019s disease on the quality of life","volume":"20","author":"Chapuis","year":"2005","journal-title":"Mov Disord"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jamda.2013.10.007","article-title":"Parkinson disease in long term care facilities: a review of the literature","volume":"15","author":"Weerkamp","year":"2014","journal-title":"J Am Med Dir Assoc"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/13696998.2019.1693383","article-title":"The effect of functional status impairment on nursing home admission risk among patients with advanced Parkinson\u2019s disease","volume":"23","author":"Shih","year":"2020","journal-title":"J Med Econ"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/1531-8257(200011)15:6<1112::aid-mds1008>3.0.co;2-a","article-title":"How does Parkinson\u2019s disease affect quality of life? A comparison with quality of life in the general population","volume":"15","author":"Schrag","year":"2000","journal-title":"Mov Disord"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/archneur.60.3.387","article-title":"Prevalence and characteristics of dementia in Parkinson disease","volume":"60","author":"Aarsland","year":"2003","journal-title":"Arch Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1212\/wnl.43.11.2227","article-title":"Risk factors for nursing home placement in advanced Parkinson\u2019s disease","volume":"43","author":"Goetz","year":"1993","journal-title":"Neurology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/ggi.12204","article-title":"Experience of care home residents with Parkinson\u2019s disease: reason for admission and service use","volume":"14","author":"Walker","year":"2014","journal-title":"Geriatr Gerontol Int"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/j.1532-5415.2000.tb06891.x","article-title":"Predictors of nursing home placement in Parkinson\u2019s disease: a population-based, prospective study","volume":"48","author":"Aarsland","year":"2000","journal-title":"J Am Geriatr Soc"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jamda.2020.06.025","article-title":"Characteristics of patients with late-stage parkinsonism who are nursing home residents compared with those living at home","volume":"22","author":"Hosking","year":"2021","journal-title":"J Am Med Dir Assoc"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/mds.10507","article-title":"Direct economic impact of Parkinson\u2019s disease: a research survey in the United Kingdom","volume":"18","author":"Findley","year":"2003","journal-title":"Mov Disord"},{"key":"ref14","first-page":"165","article-title":"Parkinson\u2019s disease society brain Bank, London: overview and research","volume":"39","author":"Daniel","year":"1993","journal-title":"J Neural Transm Suppl"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1111\/jgs.12458","article-title":"Nonmotor symptoms in nursing home residents with Parkinson\u2019s disease: prevalence and effect on quality of life","volume":"61","author":"Weerkamp","year":"2013","journal-title":"J Am Geriatr Soc"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/jgs.12027","article-title":"Motor profile and drug treatment of nursing home residents with Parkinson\u2019s disease","volume":"60","author":"Weerkamp","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"g1838","DOI":"10.1136\/bmj.g1838","article-title":"Revolutionising management of chronic disease: the ParkinsonNet approach","volume":"348","author":"Bloem","year":"2014","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"638853","DOI":"10.3389\/fneur.2021.638853","article-title":"The architecture of contemporary care networks for rare movement disorders: leveraging the ParkinsonNet experience","volume":"12","author":"van de Warrenburg","year":"2021","journal-title":"Front Neurol"},{"key":"ref19","article-title":"Multidisciplinaire richtlijn Ziekte van Parkinson","author":"van Laar","year":"2020"},{"key":"ref20","first-page":"1","article-title":"Multidisciplinaire richtlijn: Ziekte van Parkinson","volume":"1","author":"Bloem","year":"2010","journal-title":"Communications"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov Disord"},{"key":"ref22","first-page":"1","article-title":"Paramedische zorg in verpleeghuizen: een inventarisatie van omvang, inhoud en indicatiestelling van paramedische zorg","author":"Boer","year":"2004","journal-title":"Utecht"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2318-7-7","article-title":"Factors associated with physiotherapy provision in a population of elderly nursing home residents; a cross sectional study","volume":"7","author":"Leemrijse","year":"2007","journal-title":"BMC Geriatr"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1212\/01.wnl.0000295666.30948.9d","article-title":"The AMC linear disability score in patients with newly diagnosed Parkinson disease","volume":"69","author":"Weisscher","year":"2007","journal-title":"Neurology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1477-7525-2-42","article-title":"The AMC linear disability score project in a population requiring residential care: psychometric properties","volume":"2","author":"Holman","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1477-7525-3-83","article-title":"The Academic Medical Center linear disability score (ALDS) item bank: item response theory analysis in a mixed patient population","volume":"3","author":"Holman","year":"2005","journal-title":"Health Qual Life Outcomes"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1136\/jnnp.2003.017509","article-title":"A short scale for the assessment of motor impairments and disabilities in Parkinson\u2019s disease: the SPES\/SCOPA","volume":"75","author":"Marinus","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jclinepi.2004.09.014","article-title":"The SCOPA-motor scale for assessment of Parkinson\u2019s disease is a consistent and valid measure","volume":"58","author":"Mart\u00ednez-Mart\u00edn","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1212\/01.wnl.0000091864.39702.1c","article-title":"Assessment of cognition in Parkinson\u2019s disease","volume":"61","author":"Marinus","year":"2003","journal-title":"Neurology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1136\/jnnp.2006.112367","article-title":"Cognitive impairment in Parkinson\u2019s disease","volume":"78","author":"Verbaan","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1136\/jnnp.51.11.1401","article-title":"Parkinson\u2019s disease and depression: psychometric properties of the Beck depression inventory","volume":"51","author":"Levin","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mds.20792","article-title":"Reliability and validity of the Beck depression inventory in patients with Parkinson\u2019s disease","volume":"21","author":"Visser","year":"2006","journal-title":"Mov Disord"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/1531-8257(200011)15:6<1221::aid-mds1024>3.0.co;2-h","article-title":"The validity of the Beck depression inventory as a screening and diagnostic instrument for depression in patients with Parkinson\u2019s disease","volume":"15","author":"Leentjens","year":"2000","journal-title":"Mov Disord"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch Gen Psychiatry"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1212\/wnl.44.12.2308","article-title":"The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1176\/jnp.12.2.233","article-title":"Validation of the NPI-Q, a brief clinical form of the neuropsychiatric inventory","volume":"12","author":"Kaufer","year":"2000","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/mds.23467","article-title":"Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson\u2019s disease","volume":"26","author":"Post","year":"2011","journal-title":"Mov Disord"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2318-6-7","article-title":"Measuring change in activities of daily living in nursing home residents with moderate to severe cognitive impairment","volume":"6","author":"Carpenter","year":"2006","journal-title":"BMC Geriatr"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.parkreldis.2016.09.001","article-title":"Medication use in people with late stage Parkinson\u2019s disease and parkinsonism living at home and in institutional care in north-East England: a balance of symptoms and side-effects?","volume":"32","author":"Hand","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.parkreldis.2004.01.006","article-title":"Therapeutic factors causing hallucination in Parkinson\u2019s disease patients, especially those given selegiline","volume":"10","author":"Kamakura","year":"2004","journal-title":"Parkinsonism Relat Disord"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/mds.10567","article-title":"Psychosis in Parkinson\u2019s disease","volume":"18","author":"Poewe","year":"2003","journal-title":"Mov Disord"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/ane.13380","article-title":"Risk factors for minor hallucinations in Parkinson\u2019s disease","volume":"143","author":"Omoto","year":"2021","journal-title":"Acta Neurol Scand"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.parkreldis.2009.05.006","article-title":"Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson\u2019s disease and pre-existing visual hallucinations","volume":"16","author":"van Laar","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/WNF.0b013e3181a6a92b","article-title":"The effects of apomorphine on visual perception in patients with Parkinson disease and visual hallucinations: a pilot study","volume":"32","author":"Geerligs","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson\u2019s disease","volume":"351","author":"Emre","year":"2004","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S1474-4422(09)70146-2","article-title":"Memantine in patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial","volume":"8","author":"Aarsland","year":"2009","journal-title":"Lancet Neurol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1755-5949.2010.00166.x","article-title":"Effects of cholinesterase inhibitors in Parkinson\u2019s disease dementia: a review of clinical data","volume":"17","author":"van Laar","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/mds.26256","article-title":"In-patient multidisciplinary rehabilitation for Parkinson\u2019s disease: a randomized controlled trial","volume":"30","author":"Monticone","year":"2015","journal-title":"Mov Disord"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1136\/jnnp-2017-316437","article-title":"Efficacy of intensive multidisciplinary rehabilitation in Parkinson\u2019s disease: a randomised controlled study","volume":"89","author":"Ferrazzoli","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","article-title":"Evidence based medicine: what it is and what it isn\u2019t","volume":"312","author":"Sackett","year":"1996","journal-title":"BMJ"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1468-1331.2008.02380.x","article-title":"Parkinson\u2019s disease and nursing home placement: the economic impact of the need for care","volume":"16","author":"Vossius","year":"2009","journal-title":"Eur J Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1128891\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:56:59Z","timestamp":1681347419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1128891\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":51,"alternative-id":["10.3389\/fneur.2023.1128891"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1128891","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]},"article-number":"1128891"}}